Pooled efficacy and safety analysis of incobotulinumtoxinA for upper- and lower-limb spasticity in children with severe cerebral palsy (GMFCS levels IV–V)
Objective: To assess the efficacy and safety of incobotulinumtoxinA for lower-limb (LL) and upper-limb (UL) spasticity in children and adolescents with cerebral palsy (CP) and…COMPARISON OF ELECTROPHYSIOLOGIC AND ULTRASOUND GUIDANCE FOR ONABOTULINUM TOXIN-A INJECTIONS IN FOCAL UPPER EXTREMITY SPASTICITY AND DYSTONIA
Objective: To investigate two targeting techniques for onabotulinum toxin-A (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity: guidance with electrical…Neutralizing Antibody Conversion With OnabotulinumtoxinA From Global Studies Across Multiple Indications With A Focus On Movement Disorders: A Meta-Analysis
Objective: A meta-analysis of clinical trial data across 10 indications for onabotulinumtoxinA was performed to assess incidence of neutralizing antibody (nAb) formation with a focus…Disparities in Access to Spasticity Chemodenervation Specialists in the United States: a National Analysis of Medicare Data
Objective: To explore the variations in access to spasticity chemodenervation specialists across several geographical, ethnic, racial, and population density factors. Background: Equity in access to…Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects
Objective: To confirm the efficacy and safety of incobotulinumtoxinA (INCO; Xeomin®, Merz Pharmaceuticals GmbH) in East Asian subjects from study sites in Japan with post-stroke…Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update – 29 Years of Safety Observation
Objective: The present study evaluated pregnancy outcomes following onabotulinumtoxinA exposure to provide a cumulative 29-year safety update. Background: A previous publication of pregnancy outcomes in…Management of Cervical Dystonia & Spastic Paresis with Botulinum Neurotoxin-A: results from the INPUT survey
Objective: To describe current practices among physicians using botulinum toxin-A (BoNT-A) to treat spastic paresis (SP) and cervical dystonia (CD). Background: BoNT-A is an effective…Multi-level and multi-pattern lower- and upper-limb spasticity treatment with incobotulinumtoxinA in children and adolescents with cerebral palsy
Objective: Assess efficacy and safety of incobotulinumtoxinA in lower-limb (LL) or combined LL/upper-limb (LL/UL) spasticity in children and adolescents with cerebral palsy (CP). Background: Ambulant…Phenotyping spasticity-associated tonic spasms: implications for therapy
Objective: To evaluate common phenotypes of tonic spasms (TS) in patients with spasticity and inform therapeutic interventions. Background: Spasticity can be associated with several hyperkinetic…Treatment with Botulinum Toxin for Refractory Fever caused by Severe Spasticity
Objective: Present a series of cases of patients with refractory fever associated to spasticity secondary to a brain or spinal cord injury who developed refractory…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.